Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05150288
Other study ID # 1806INF- DACH
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 8, 2019
Est. completion date July 24, 2020

Study information

Verified date November 2021
Source Nestlé
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Human milk oligosaccharides (HMOs) represent the third largest solid component of breast milk. Technology advancements made it possible to supplement infant formulas with HMOs (2'FL, LNnT). Two published RCTs have demonstrated that infant formulas supplemented with 2'FL or 2'FL+LNnT are safe, well-tolerated, support normal grow, and may support healthy GI function and confer immune benefits. The performance of HMOs-supplemented formulas assessed in a real-world setting is complementary to previously conducted RCTs conducted in highly controlled clinical settings. Main objectives will be to monitor the safety & tolerance of HMOs-supplemented formulas in larger and diverse infant populations; to assess the performance of HMOs-supplemented formulas in mixed-fed infants, a population that was not studied in previous RCTs but likely represents a relatively common feeding regimen. Finally, considering the potential health/immune benefits of HMOs, it is also important explore the incidences of illnesses (i.e., respiratory illnesses, GI illnesses, and fever) associated with consuming HMOs-supplemented formulas and compare with breastfed infants data.


Description:

Objectives: The main objective of this study is to document the growth and feeding tolerance of healthy term infants consuming an infant formula supplemented with HMOs for 8 weeks (56 days), in a real-world setting. Main endpoints: 1. Growth documented via monitoring the anthropometric parameters including weight, length, head circumference, BMI and their corresponding z-scores (i.e., z-scores for weight-for-age, length-for-age, weight-for-length, head circumference-for-age, and BMI-for-age) calculated using the 2006 WHO Growth Standards 2. Feeding tolerance assessed via monitoring parent-reported overall GI symptom burden measured by the Infant Gastrointestinal Symptom Questionnaire (IGSQ) index score (13-item summary score) Additional objectives: To describe the following outcomes in infants fed an infant formula supplemented with HMOs: 1. Formula acceptability 2. Despite there are no expected safety concerns, standard Adverse Events (AEs) monitoring will be implemented during the study Additional endpoints: 1. Formula acceptability assessed by the Study Formula Satisfaction Questionnaire 2. Reported AEs and Serious Adverse Events (SAEs) including type, incidence, severity, seriousness and relation to study formula consumption as well as concomitant medications and non-pharmacological treatments. - Select morbidities of interest (i.e., respiratory illnesses, GI illnesses, and fever) will be collected as part of AE reporting and specific corresponding AE guidance forms will be used to standardize reporting of such AEs Trial design: Uncontrolled, single arm, open-label, prospective study in infants (enrolled at postnatal age 7 days to 2 months) fed the study formula for 8 weeks (56 days) A group of exclusively breastfed infants (BF) will serve as a reference group in parallel to the study arm. For the BF group, Infants must have been exclusively consuming breast milk since birth, and their parent(s) must have made the decision to continue exclusively breastfeeding until at least 4 month of age Trial population: Healthy, male and female, term infants, 7 days postnatal age to 2 months of age at the enrollment Treatment duration: Total study participation/intervention up to approximately 8 weeks


Recruitment information / eligibility

Status Completed
Enrollment 106
Est. completion date July 24, 2020
Est. primary completion date July 24, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 2 Months
Eligibility Inclusion Criteria: - Evidence of personally signed and dated informed consent document indicating that the infant's parent(s) have been informed of all pertinent aspects of the study - Parent(s) are willing and able to fulfill the requirements of the study protocol - Healthy full term (37-42 weeks gestation) infant - Be between post-natal age (Date of Birth = Day 0) 7 days to 2 months - Parent(s) must have independently elected, before enrollment, to formula feed Exclusion Criteria: - Any known intolerance/allergy to cow's milk (formula-fed group only) - systemic disorders (cardiac, respiratory, endocrinological, hematologic, gastointestinal, or other) - conditions requireing infant feedings other than those specified in the protocol - Infants must have been exclusively consuming breast milk since birth, and their parent(s) must have made the decision to continue exclusively breastfeeding until at least 4 month of age

Study Design


Intervention

Other:
HMO-supplemented infant formula
Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides

Locations

Country Name City State
Austria Facharzt für Kinder- und Jugendheilkunde Oberwart
Germany Kinder- und Jugensarztpraxis Berlin
Germany Evangelisches Waldkrankenhaus Spandau Berlin-Spandau
Germany Facharzt für Säuglings-, Kinder- und Jugendmedizin Bremen
Germany Facharztpraxis für Kinder- und Jugendmedizin Burglengenfeld
Germany Praxis Dr. Klee Bürstadt
Germany Kinderarztpraxis Düsseldorf
Germany Praxis Al-Radhi Ehingen
Germany Gemeinschaftspraxis Kinder- und Jugendarztpraxis Geldern
Germany Kinder und Jugendarztpraxis Leinfelden-Echterdingen
Germany Kinderarztpraxis Köllges Mönchengladbach
Germany Kinder- und Jugendärztliche Gemeinschaftspraxis Oberhausen
Germany Zentrum für Kinder- und Jugendgesundheit Regensburg
Germany Kinder- und Jugendarztpraxis Schwabach
Germany Kinder- und Jugendarzt Viersen
Switzerland Nestlé Research, Société des Produits Nestlé S.A. Lausanne
Switzerland Global Medical Affairs, Société des Produits Nestlé Vevey

Sponsors (18)

Lead Sponsor Collaborator
Nestlé Facharzt für Kinder- und Jugendheilkunde Dr. Faustmann, Oberwart, Facharzt für Säuglings-, Kinder- und Jugendmedizin, Bremen, Facharztpraxis für Kinder- und Jugendmedizin Dr. Aulinger, Burglengenfeld, Gemeinschaftspraxis Kinder- und Jugendpraxis Dr. Stepan Dreher und Tina Hübler, Geldern, Global Medical Affairs, Société des Produits Nestlé S.A., Vevey, Switzerland, Kinder und Jugendarztpraxis Dr. Maier, Leinfelden-Echterdingen, Kinder- und Jugendarzt Dr. Umpfenbach und Dr. Lorenz, Viersen, Kinder- und Jugendärztliche Gemeinschaftspraxis Bedikian & Bouikidis, Oberhausen, Kinder- und Jugendarztpraxis Dr. Kröckel, Dr. Ciesla, Berlin, Kinder- und Jugendarztpraxis Schwabach, Kinderarztpraxis Dr. Zakarian, Düsseldorf, Kinderarztpraxis Köllges, Mossakowski und Meyer-Krott, Mönchengladbach, Nestlé Research, Société des Produits Nestlé S.A., Lausanne, Switzerland, Praxis Al-Radhi, Ehingen, Praxis Dr. Klee, Bürstadt, Waldkrankenhaus Protestant Hospital, Spandau, Zentrum für Kinder- und Jugendgesundheit Regensburg

Countries where clinical trial is conducted

Austria,  Germany,  Switzerland, 

References & Publications (1)

Storm HM, Shepard J, Czerkies LM, Kineman B, Cohen SS, Reichert H, Carvalho R. 2'-Fucosyllactose Is Well Tolerated in a 100% Whey, Partially Hydrolyzed Infant Formula With Bifidobacterium lactis: A Randomized Controlled Trial. Glob Pediatr Health. 2019 Mar 15;6:2333794X19833995. doi: 10.1177/2333794X19833995. eCollection 2019. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary World Health Organization (WHO) based weight-for-age z-scores Weight-for-age z-scores using WHO growth standards 8 weeks (study end)
Primary World Health Organization (WHO) based length-for-age z-scores Length-for-age z-scores using WHO growth standards 8 weeks (study end)
Primary World Health Organization (WHO) head-circumference-for-age z-scores head-circumference-for-age z-scores using WHO growth standards 8 weeks (study end)
Primary World Health Organization (WHO) based body-mass-index (BMI)-for-age z-scores Weight and height will be combined to calculate BMI in kg/m^2, then BMI-for-age z-scores will be derived using WHO growth standards 8 weeks (study end)
Primary Feeding tolerance The Infant Gastrointestinal Symptom Questionnaire (IGSQ) index score will be used to assess GI distress. This is a validated 13-item questionnaire where each item is scored on a scale of 1 to 5 with higher values indicating greater GI distress. A composite IGSQ score is derived from summing the individual scores with a possible range of 13 to 65 where higher values indicate greater GI distress and values =23 indicate no digestive distress 4 weeks (study midpoint)
Primary Feeding tolerance The Infant Gastrointestinal Symptom Questionnaire (IGSQ) index score will be used to assess GI distress. This is a validated 13-item questionnaire where each item is scored on a scale of 1 to 5 with higher values indicating greater GI distress. A composite IGSQ score is derived from summing the individual scores with a possible range of 13 to 65 where higher values indicate greater GI distress and values =23 indicate no digestive distress 8 weeks (study end)
Secondary Formula acceptability Study Formula Satisfaction Questionnaire 4 weeks (study midpoint), 8 weeks (study end)
Secondary Standard adverse events (AEs) reporting for safety assessment Reported adverse events (AEs) and Serious Adverse Events (SAEs) include type, incidence, severity, seriousness and relation to feeding From the time the informed consent form has been signed at enrollment infant age less than 7 days to 2 months through the 8 weeks of intervention
Secondary Weight Weight measurements in grams 8 weeks (study end)
Secondary Length Length measurements in centimeters 8 weeks (study end)
Secondary Head circumference Head circumference measurements in centimeters 8 weeks (study end)
Secondary Body-mass-index (BMI) Weight and height will be combined to report BMI in kg/m^2 8 weeks (study end)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05551975 - Preterm Infants Fed a Human Milk Fortifier N/A
Completed NCT01721512 - The Growth and Development of Breast and Formula Fed Term Asian Infants N/A
Completed NCT01162798 - Preterm Infant Growth N/A
Active, not recruiting NCT00970398 - Effect of an Infant Formula on Infant Growth, Health and Immune Functions N/A
Completed NCT01666457 - Impact of Implementing an Infant Driven Feeding Program on Oral Feeding and Growth Outcomes of Medically Fragile Infants in the Neonatal ICU (NICU)
Completed NCT00808756 - Study on Fermentable Carbohydrates in Healthy Infants N/A
Completed NCT00997971 - Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein Phase 3
Completed NCT03276663 - Growth of Healthy Term Infants Fed a Partially Hydrolyzed Follow-up Formula N/A
Recruiting NCT02695784 - Probiotics After Discharge Phase 4
Withdrawn NCT02860026 - Growth and Tolerance of Healthy Term Infants Fed Cow's Milk-Based Infant Formulas N/A
Completed NCT01128517 - Maternal Education on Complementary Feeding and Infant Outcome N/A
Completed NCT00282113 - Effects of Probiotic and Prebiotic Combinations on Premature Infants N/A
Completed NCT03276884 - Growth and Tolerance of Young Infants N/A
Completed NCT04055363 - Human Milk Oligosaccharides (HMOs) Post-market Study on Infants N/A
Completed NCT05302427 - Infant Massage and Infant Growth, Mother-Infant Attachment, and Maternal Self-Confidence N/A
Not yet recruiting NCT05616117 - Next-generation Effects of Vitamin D Supplementation in Pregnancy
Active, not recruiting NCT02410057 - Growth and Metabolism in Infants Fed Protein-reduced, Alpha-lactalbumin Enriched Formula N/A
Completed NCT01158352 - Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Innovative Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children N/A
Completed NCT01109849 - Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth Phase 4
Completed NCT01210391 - Growth of Infants Fed an Extensively Hydrolyzed Infant Formula N/A